Publications and Digital Products

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.

This quick guide helps clinicians address viral hepatitis when working with people living with substance use disorders. It covers hepatitis prevention, screening, treatment, and service coordination, and guides administrators on how to add or improve hepatitis services.

This manual assists behavioral health professionals who treat people living with substance use disorders in understanding the implications of a hepatitis diagnosis. It discusses screening and referrals, and explains how to evaluate a program's hepatitis practices. Access the literary review.

This manual provides physicians with quick reference information about three FDA-approved medications to help patients achieve abstinence from alcohol: acamprosate, disulfiram, and naltrexone (oral and extended-release). It also includes patient management tips.